Thalidomide-amido-PEG2-NH2 is primarily utilized in the development of PROTACs (Proteolysis Targeting Chimeras), a cutting-edge technology in drug discovery. This compound serves as a key linker component that connects a target protein-binding ligand to an E3 ubiquitin ligase recruiter. By facilitating the ubiquitination and subsequent degradation of specific proteins, it plays a crucial role in targeting disease-causing proteins that are traditionally considered "undruggable." Its application is particularly significant in cancer research, where it aids in the selective degradation of oncogenic proteins, offering a novel therapeutic strategy. Additionally, its use extends to neurodegenerative and inflammatory diseases, providing a versatile tool for advancing targeted protein degradation therapies.